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A B S T R A C T
Purpose
Cancer screening strategies have commonly adopted single-biomarker thresholds to identify
abnormality. We investigated the impact of serial biomarker change interpreted through a risk
algorithm on cancer detection rates.
Patients and Methods
In the United Kingdom Collaborative Trial of Ovarian Cancer Screening, 46,237 women, age 50
years or older underwent incidence screening by using the multimodal strategy (MMS) in which
annual serum cancer antigen 125 (CA-125) was interpreted with the risk of ovarian cancer
algorithm (ROCA). Women were triaged by the ROCA: normal risk, returned to annual screening;
intermediate risk, repeat CA-125; and elevated risk, repeat CA-125 and transvaginal ultrasound.
Women with persistently increased risk were clinically evaluated. All participants were followed
through national cancer and/or death registries. Performance characteristics of a single-threshold
rule and the ROCA were compared by using receiver operating characteristic curves.
Results
After 296,911 women-years of annual incidence screening, 640 women underwent surgery. Of
those, 133 had primary invasive epithelial ovarian or tubal cancers (iEOCs). In all, 22 interval iEOCs
occurred within 1 year of screening, of which one was detected by ROCA but was managed
conservatively after clinical assessment. The sensitivity and specificity of MMS for detection of
iEOCs were 85.8% (95% CI, 79.3% to 90.9%) and 99.8% (95% CI, 99.8% to 99.8%), respectively,
with 4.8 surgeries per iEOC. ROCA alone detected 87.1% (135 of 155) of the iEOCs. Using fixed
CA-125 cutoffs at the last annual screen of more than 35, more than 30, and more than 22 U/mL
would have identified 41.3% (64 of 155), 48.4% (75 of 155), and 66.5% (103 of 155), respectively.
The area under the curve for ROCA (0.915) was significantly (P  .0027) higher than that for a
single-threshold rule (0.869).
Conclusion
Screening by using ROCA doubled the number of screen-detected iEOCs compared with a fixed
cutoff. In the context of cancer screening, reliance on predefined single-threshold rules may result
in biomarkers of value being discarded.
J Clin Oncol © 2015 American Society of Clinical Oncology. Licensed under the Creative
Commons Attribution 3.0 License: http://creativecommons.org/licenses/by/3.0/
INTRODUCTION
Akey component of cancer control is screening, and
significant research is underway to develop highly
sensitive and specific tests that are minimally inva-
sive.Circulatingbiomarkershaveamajor role in this
effort. Many are not specific to the cancer because
they are altered in othermalignant or benign condi-
tions. Therefore, it is essential to carefully define the
cutoff for abnormality. Frequently, biomarker levels
are interpreted by using a single-threshold rule de-
veloped in the context of differential diagnosis of
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clinically presenting cancers. Biomarker velocity, which can be
significantly different in patients with cancer compared with con-
trols1 is often ignored. Where it has been used, the data may be
conflicting as they are for prostate-specific antigen velocity in
prostate cancer2-4 or limited as they are for ovarian cancer.1,5,6
Modeling studies5,6 that use data from the Prostate, Lung, Colo-
rectal andOvarian (PLCO)Cancer ScreeningTrial7 suggest that up
to a third of the ovarian cancer cases could have been detected
earlier if cancer antigen 125 (CA-125) velocity had been used
instead of a fixed cutoff.
In themultimodal screening (MMS)armof theUnitedKingdom
Collaborative Trial of Ovarian Cancer Screening (UKCTOCS),
women underwent serial serum CA-125 testing.8,9 CA-125 velocity
was interpreted by using a risk of ovarian cancer algorithm (ROCA),
which compares an individual’s serial profile with that of cases and
controls to estimate the risk of having ovarian cancer.10 We report
here on the impact of using CA-125 velocity compared with a single-
threshold rule on ovarian cancer detection during 296,911 woman-
years of annual incidence screening.
PATIENTS AND METHODS
The trial was approved by theUnitedKingdomNorthWestMulticentre
Research Ethics Committee (International Standard Randomized Con-
trolled Trial Number ISRCTN22488978 and ClinicalTrials.gov
NCT00058032). Trial design, including details of recruitment and ran-
domization, and the results of the initial (prevalence) screen have been
described elsewhere.8,9 All womenprovidedwritten informed consent.
In brief, between 2001 and 2005, 202,638 women were ran-
domly assigned, 50,640 ofwhomwere allocated to theMMSgroup.
Of those, 50,078 (98.9%) underwent a prevalence screen (Fig 1).
The sensitivity, specificity, and positive predictive values (PPVs)
for detection of invasive epithelial ovarian and/or tubal cancers
(iEOCs) within 1 year of first screen (the prevalence screen) were
89.5%, 99.8%, and 35.1%, respectively.9
MMS Strategy
Following the initial prevalence screen, trial participants under-
went an annual blood test on the anniversary of the randomization
Assessed for eligibility
(N = 1,243,282)
Excluded
   Not meeting inclusion criteria
   Declined to participate
   Not recruited as target reached
 
   (n = 79,627)
   (n = 950,825)
 (n = 10,192)
Randomly assigned
(n = 202,638)
Current analysis
Allocated to 
control group: 
nonintervention
 (n = 101,359)
Intervention incidence screen
   Underwent incidence screening  
   Did not attend any incidence screening 
      Died 
      Ovaries removed 
      Declined 
 
   (n = 46,237)*
   (n = 4,403) 
      (n = 104) 
      (n = 157) 
      (n = 4,142) 
Follow-up at least 2 years after last incidence screen
   Did not have 2 years of follow-up  
   Discontinued incidence screening before 
      2011 (end of trial intervention) 
         Died 
         Ovaries removed 
         Declined 
 
   (n = 186 of 46,237)
   (n = 16,282)
        
      (n = 1,329)
      (n = 825)
(n = 14,128)
Analyzed
   Excluded those who did not attend any
      incidence screening
*Five women who did not attend for prevalence screening intervention subsequently attended incidence screening.
(n = 46,237) 
(n = 4,403)
Allocated to 
ultrasound group: 
intervention
 (n = 50,639)
Allocated to multimodal group: 
intervention
(n = 50,640)
Underwent prevalence screen
(n = 50,078)
Fig 1. CONSORT diagram.
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date. Serum CA-125 (level I screen) was measured by using an
electrochemiluminescence sandwich immunoassay (Catalog No.
11776223 322; Roche Diagnostics, Mannheim, Germany).10 The
screeningprotocol andmanagementof screen-detectedabnormalities
have been previously described8,9 and are illustrated in Figure 2. In
brief, at the annual screen, women were triaged as follows: risk of
ovarian cancer (ROC) normal, return to annual screening; ROC in-
termediate, repeat CA-125 (repeat level I screen) in 12 weeks; and
ROC elevated, repeat CA-125 and transvaginal scan (TVS; level II
screen) in 6 weeks, with earlier screens arranged when results are
suggestive of clinical disease. At level II screen,womenwith normal or
intermediateROCand anormal scanwere returned to annual screen-
ing, whereas those with elevated ROC and a normal scan or an unsat-
isfactory scan irrespective of ROC had a repeat level II screen in 6
weeks. Those with abnormal scans irrespective of ROC were referred
for clinical assessment. At repeat level II, womenwere again triaged to
Repeat CA125 in 12 weeks
(n = 24,788)
Repeat CA125 in 12 weeks
(n = 8,500)
Repeat level II screen in 6 weeks
(n = 2,766)
Level II screen in 6 weeks
(n = 7,323)
E ROC      (n = 1,524)  I ROC  (n = 8,644) N ROC     (n = 14,620)
Level I screen - CA125
(N = 296,911)
E ROC (n = 4,451) )331,52 = n(COR I N ROC (n = 267,327)
LII (n = 2)
CE (n = 5)
LII (n = 2)
LI (n = 55)
LI (n = 175)
SD
CE
(n = 463)
(n = 55)
SD
CE
(n = 176)
(n = 136)
SD
CE
(n = 162)
(n = 384)
SD
CE
(n = 170)
(n = 29)
E ROC
I ROC
(n = 655)
(n = 1,231)
A scan +
   any ROC
(n = 1,023)
A scan or
   S ROC
(n = 539) N scan + E 
   ROC U scan + 
   E/I ROC
(1,267) N scan + N/I 
   ROC U scan 
   + N ROC
(n = 960)
N scan + E ROC or 
   U scan
(n = 3,312) N scan with N or 
   I ROC
(n = 2,988)
N ROC (n = 6,614)
SD (n = 29)
SD (n = 35)
CE (n = 994) CE (n = 504) CE (n = 1,222)
Annual
   screening
(n = 292,497)
SD (n = 45)
SD (n = 5)
Outcome of CE
(n = 3,329)
Review of screening results alone:
   Annual screening
   
Clinically assessed:
   Surgery
   Other cancer
   Other disease
   Annual screening
 
   (n = 507)
   
 
      (n = 640)
   (n = 128)
(n = 23)
   (n = 2,031)
Fig 2. Multimodal screening algorithm
and outcome of incidence screening. A,
abnormal; CA-125, cancer antigen 125;
CE, clinical evaluation; E, elevated; I, inter-
mediate; LI, level I CA-125 test; LII, level II
transvaginal scan (TVS) and CA-125 test;
N, normal; ROC, risk of ovarian cancer; S,
severe; SD, screening discontinued; U,
unsatisfactory.
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annual screening or clinical assessment (Fig 2).Womenwith an ROC
of more than 1 in 5 (severe risk) were recommended to have surgery
irrespective of scan findings.
The protocol was strictly enforced by using a custom-built Web-
based trialmanagement systemwith central classification of results, sub-
sequent actions, and automated screening appointments.9 At study
conception, the ROC cutoffs ( 1 in 1,818 and 1 in 500) were set to
allowapproximately15%and2%ofwomentobetriagedatannualscreen
to intermediate and elevatedROCgroups, respectively. InApril 2005, on
the basis of data analysis on the performance of ROCA within UKC-
TOCS, the cutoffsweredecreased to less than1 in3,500and less than1 in
1,000, respectively, tomaintain the target proportions for triage.
Clinical Assessment, Surgery, and
Conservative Management
Clinical assessment and appropriate investigations were under-
taken locally by a designated clinician. The latter included repeat
CA-125, imaging (TVS with Doppler ultrasound, computed tomog-
raphy, and/or magnetic resonance imaging of abdomen and pelvis)
and other tumor markers. In women with severe ROC, a chest com-
puted tomography scan and mammogram were also requested. All
women who were thought to have cancer were discussed at the local
gynecologic oncology multidisciplinary teammeeting. If surgery was
recommended, laparoscopic bilateral salpingo-oophorectomy was
performedunless the assessmentwasdefinitively suggestiveof ovarian
cancer or the procedurewas inappropriate for other reasons, inwhich
case laparotomy was preferred. Women who underwent bilateral
salpingo-oophorectomy andwere found to have ovarian and/or tubal
cancerhadcompletionsurgerywith staging. In thosewhodidnothave
surgery, the coordinating center was informed of the follow-up plan,
which usually involved repeat CA-125/TVS every 3 months. When
clinicians felt reassured that the woman was unlikely to have ovarian
cancer, she was returned to annual screening within UKCTOCS.
All center staff were asked to report intra- and postoperative
complications, return to operating theater, and readmissions by
using standardUKCTOCS forms and to report any serious adverse
events to a designated safety officer. In addition, coordinating
center staff reviewed medical notes and follow-up questionnaire
responses to capture any additional complications. All were inde-
pendently reviewed by a senior trial gynecologic oncologist blinded
to the randomization group.
Confirmation of Diagnosis
In all women who underwent screen-positive surgery, copies of
medical records including surgery notes, discharge letters, and histo-
pathology and/or cytology reports were obtained as previously de-
scribed.9 For womenwho resided in England, additional information
up toMarch 31, 2010, was obtained from theHospital Episode Statis-
tics.11 In women diagnosed with cancer, further information was
obtained, including the discharge summary, multidisciplinary team
meeting notes, and other correspondence. These reports were also
obtained for all women when there was notification through cancer
registry, death certificate, follow-up questionnaire, or personal com-
munication of a possible ovarian or tubal cancer (International Clas-
sification of Diseases and Related Health Problems [10th revision;
ICD-10] codes; AppendixTableA1, online only). The case notes of all
these individuals were reviewed using a strict protocol by an Out-
comes Review Committee (two pathologists and two gynecologic
oncologists) who were blinded to the randomization group. They
confirmed the final diagnosis, stage, and morphology of any cancer
and, when possible, they classified iEOCs into type I (low-grade se-
rous, low-grade endometrioid, mucinous, and clear cell cancers) or
type II (high-grade serous, high-grade endometrioid, carcinosarco-
mas, and undifferentiated carcinoma) cancers.12 Where it was not
possible to delineate whether the primary site was ovary, fallopian
tube, or peritoneum, the diagnosis was classified as undesignated.13
Follow-Up
All volunteers were followed up through their National
Health Service number by the appropriate national agencies for
cancer registrations and/or deaths as well as by postal question-
naires 3 to 5 years after randomization and 2 years after the end of
screening in the trial.9 Themost recent cancer registrations for this
analysis were received on June 17, 2014 (England and Wales), and
July 2, 2014 (Northern Ireland).
Analysis
A screenwas defined as a single or series of serumCA-125 assays
with or without scans culminating in surgery or return to annual
screening. All women were censored at 1 year from last scan and/or
CA-125assayperformedduring their last incidence screen.The screen
was considered positive (screen positive) if the woman had surgery or
image-guided biopsy as a result of screening. Included in this category
were womenwhowere found to have ovarian lesions during imaging
for other disease and who underwent surgery while awaiting repeat
testing. The primary outcome for this analysis was primary iEOC
diagnosed within 12 months of the last test in the incidence screen.
Women with primary peritoneal cancer, borderline or nonepithelial
ovarian cancers, and ovarian neoplasms of uncertain behavior were
not included as true positives in the primary outcome analysis. A
screen-detected cancer was one that resulted from screen-positive
surgery and/or biopsy. A screen-negative/interval cancer was one di-
agnosed clinically within 12 months of the last test in the incidence
screen in women returned to annual screening.
Overall sensitivity, specificity, PPV, and descriptive statistics for
MMSwerecalculated for iEOCsand forall primarymalignantovarian
and fallopian tube cancers (including borderline tumors and nonepi-
thelial ovarian cancers).9Receiveroperating characteristic curveswere
constructed to compare the performance characteristics of annual
serum CA-125 interpreted by using the ROCA with that of CA-125
interpreted by using several normal fixed cutoffs in this population,
specifically, more than 35, more than 30, and more than 22 U/mL. A
test for the difference in the area under the curves (AUCs) was per-
formed as described by DeLong et al.14
RESULTS
The CONSORT diagram (Fig 1) shows that 46,237 (91.3%) of the
50,640 women randomly assigned to the MMS arm participated in
incidence screening. Between June 25, 2002, and December 21, 2011,
296,911 incidence screens were undertaken. Appendix Table A2 (on-
line only) lists the reasons for screens that were not performed. The
median number of incidence screens was seven (range, one to 10;
interquartile range [IQR], six to eight). Median follow-up from the
last incidence screen to latest cancer registration update was 3.1 years
(IQR, 2.8 to 4.1 years).
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Figure 2 and Appendix Table A3 (online only) summarize the
results. In all, 10.0% (29,584 of 296,911 involving 20,485 of 46,237
volunteers) of annual screens resulted in a recommendation for a
repeat screen. Use of a single-threshold rule for CA-125 of more than
35,more than 30, ormore than 22U/mLwould have resulted in 1.9%
(5,597 of 296,911 involving 2,253 of 46,237 volunteers), 3.3% (9,699
of 296,911 involving 3,537 of 46,237 volunteers), and 9.7% (28,757 of
296,911 involving 8,596 of 46,237 volunteers), respectively, of screens
needing to be repeated.
Overall, 1,085 (0.4%of 296,911) of these screening episodeswere
not completed because women died (n 95), changed their minds/
moved away/did not attend repeat appointments (n  689), were
diagnosed with nonovarian cancer (n  169) or other disease (n 
29), or had their ovaries removed as part of surgery for other condi-
tions (n 20).
Clinical evaluationwasperformedin1.1%(3,329of296,911 involv-
ing 3,078 of 46,237 volunteers) of the screens (Fig 2). In 507 patients this
was limitedtoassessmentofscreenresultsandreturntoannualscreening.
The remaining 2,822 screens resulted in clinical assessment; 3.6%(102of
2,822)of theassessmentswereundertaken insteadofprotocol-mandated
repeat testing. Reasons stated included CA-125 levels 50 U/mL (n
50), elevatedROC(n68), or both (n38) andpatient anxiety and/or
symptoms suggestive of ovarian cancer (n 22).
A proportion of the screens (0.2%; 640 of 296,911) resulted in
womenhaving screen-positive surgery, 64.8% (415 of 640) ofwhichwas
laparoscopic.Primaryovarianand/ortubalmalignanciesweredetectedin
154 (24.1%)of the 640women (Table 1). The latter included133 iEOCs,
17 borderline, and four nonepithelial ovarian cancers. Two of the 154
women had incomplete screening episodes, and ovarian cancer (one
iEOC,onenonepithelialmicroscopicgranulosa tumor)wasdiagnosed in
thecourseofimagingforrenaldiseaseandsurgeryforendometrialcancer,
respectively, while awaiting repeat testing. Thirty-two interval ovarian or
tubal cancers (22 iEOCs, nine borderline ovarian tumors, and one non-
epithelial ovarian cancer) were diagnosed clinically within 12months of
thelast incidencescreentest.The22iEOCsincludeaprotocoldeviationin
which the clinical team returned an asymptomatic woman estimated by
ROCAtobe at severe risk (one in four) to annual screening.HerCA-125
was 29U/mL and pelvicmagnetic resonance imagingwas normal. Eight
monthslater, shepresentedsymptomaticallywithhigh-gradeserousstage
III iEOC (Table 1). In addition, a second woman was classified as inter-
mediate risk by ROCA at both annual and first repeat screens but then
classified as normal risk on her second repeat sample, at which point she
wasreturnedtoannualscreening.Elevenmonths later, shewasdiagnosed
with stage IV high-grade serous cancer. An additional 21 iEOCs were
diagnosed 12 to 24months after the last annual screen.
Table 1. Pathologic Findings and CA-125 at Relevant Annual Screen (level I) in Screen-Positive Women and Screen-Negative Women
(those with interval cancers)
Outcome of Screen-Positive Surgery
Total No. of
Women
Annual CA-125
 35 U/mL  35 U/mL
Total No. of women 640 455 185
Total No. of women with normal or benign pathology 441 344 97
Laparoscopy, ovaries normal, not removed 13 12 1
Normal ovaries† 133 106 27
Benign ovarian pathology‡ 295 226 69
Total No. of nonovarian malignant neoplasms 45 24 21
Ovarian neoplasm of uncertain behavior (ICD D39.1) 2 2 0
Primary peritoneal cancer (ICD C48.2) 12 6 6
Other nonovarian and/or tubal cancer involving ovaries (secondary ovarian neoplasm) 12 6 6
Other nonovarian and/or tubal cancer not involving ovaries§ 19 10 9
Total No. of screen-positive women diagnosed with malignant neoplasm of ovary (ICD C56) and
fallopian tube (ICD C57.0) 154 87 67
Nonepithelial neoplasm of ovary (ICD C56) 4 3 1
Primary borderline epithelial neoplasm of ovary (ICD C56) 17 14 3
Primary invasive epithelial neoplasm of ovary (ICD C56) 113 56 57
Primary invasive epithelial neoplasm of fallopian tube (ICD C57.0) 11 8 3
Undesignated (unable to delineate whether primary site is ovary, fallopian tube, or peritoneum) 9 6 3
Total No. of women with screen-negative (interval) malignant neoplasm of ovary (ICD C56) or
fallopian tube (ICD C57.0) diagnosed within 1 year of end of screen 32 31 1
Nonepithelial neoplasm of ovary (ICD C56) 1 1 0
Borderline epithelial neoplasm of ovary (ICD C56) 9 9 0
Primary invasive epithelial neoplasm of ovary (ICD C56) 18 17 1
Primary invasive epithelial neoplasm of fallopian tube (ICD C57.0) 1 1 0
Undesignated (unable to delineate whether the primary site is ovary, fallopian tube, or peritoneum) 3 3 0
Abbreviations: CA-125, cancer antigen 125; ICD, International Statistical Classification of Diseases and Related Health Problems (10th revision).
Includes a volunteer who had ultrasound-guided aspiration of ascites in her year 4 screen with normal cytology and was returned to annual screening. In her next
screen, she had screen-positive laparotomy with a final diagnosis of colorectal primary metastatic to the ovaries.
†Includes five women with para-tubal cysts, three with benign hydrosalpinx, one with mucinous cystadenoma of the appendix, and one with tumor-bearing
endometrium.
‡Includes one volunteer who had benign ovarian cysts at surgery. However, CA-125 continued to increase, and 1 year later, she was diagnosed with primary
peritoneal cancer.
§Includes six women who also had benign ovarian pathology.
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At the relevant annual screen, median serum CA-125 in the 133
women with screen-detected iEOCs was 33.6 U/mL (IQR, 21.3 to
109.2). Seventy (52.6%) of 133 of these women had CA-125 levels
within the normal range ( 35 U/mL; subgroup A), and the remain-
ing 63 (47.4%)had increasedCA-125 levels ( 35U/mL; subgroupB;
Table 2). Only one of the 22 women who had an interval iEOC had a
CA-125 level more than 35 U/mL (36.9 U/mL). These results are
showngraphically inFigure3, inwhich the serial annualCA-125 levels
of all screen-positive (n  133) and screen-negative patients with
iEOC (n 22) are plotted with the annual CA-125 levels for all other
women shown as a scatterplot. The ROCA had a significantly larger
area under the curve (0.915) than the individual CA-125 measure-
ments (0.869; P  .0027; Fig 4). The sensitivity of ROCA alone was
87.1% (95% CI, 80.8% to 91.9%) and that of using annual serum
CA-125 cutoffs of more than 35, more than 30, and more than 22
U/mLwere 41.3%, (95%CI, 33.5% to49.5%), 48.4%(95%CI, 40.3%
to 56.5%), and 66.5% (95% CI, 58.4% to 73.8%), respectively. The
specificity of annual ROCA alone was 87.6%. At the same specificity,
the sensitivity of the annual CA-125 cutoff (20.99 U/mL) was 68.4%.
Of the screen-detected iEOCs, 82.0% (109 of 133) were type II.
Thedistributionsof type Iandtype II cancers in theAandBsubgroups
were similar (Table 2). Fifty-five (41.4%) of 133 patients with iEOCs
were diagnosed in stage I to II (Table 2). A greater proportion (P
.075) in subgroup A (48.6%; 34 of 70) were early-stage (stage I to II)
cancers compared with subgroup B (33.3%; 21 of 63).
Overall, inwomenwith screen-detected iEOCs, themedian time
from last screen test to surgery was 8 weeks (IQR, 4.9 to 13.7 weeks),
and themedian time fromthe start of the relevant annual screen (level
I) to surgery was 20 weeks (IQR, 11 to 34 weeks). In subgroup A,
the interval was significantly (P .0001) longer (30 weeks; IQR, 18
to 43 weeks) compared with subgroup B (12 weeks; IQR, 7 to 19
weeks). This difference reflects the greater proportion of cases
undergoing repeat screens following an intermediate ROC at an-
nual screen in subgroup A (33 of 70) compared with subgroup B
(four of 63; Table 2).
Theoverall sensitivityandspecificityofMMSfor iEOCswere85.8%
(95%CI,79.3%to90.9%)and99.8%(95%CI,99.8%to99.8%), respec-
tively, with 4.8 surgeries per iEOC detected during incidence screening
Table 2. CA-125 at the Relevant Annual Screen by Stage and Type of Primary Invasive Epithelial Ovarian and Tubal Cancers
Characteristic
Screen-Detected Status
Positive Negative
All
Annual CA-125
 35 U/mL (subgroup A)
Annual CA-125  35 U/mL
(subgroup B) All
No. % 95% CI No. % 95% CI No. % 95% CI No. % 95% CI
Total No. of women 133 70 63 22
Serum CA-125 at corresponding annual
screen, U/mL
Median 33.6 21.8 112.1 13.6
IQR 21.3-109.2 16.5-26.3 66.4-375.4 11-20.8
ROC at corresponding annual screen
Normal risk 0 0 0 0 0 0 20 90.9
Intermediate risk 37 27.8 33 47.1 4 6.3 1 4.5
Elevated risk 96 72.2 38 54.3 58 92.1 1 4.5
Stage
I 35 22 13 4
II 20 12 8 2
III 68 32 36 11
IIIa 6 2 4 0
IIIb 16 11 5 3
IIIc 46 19 27 8
IV 10 4 6 5
Early stage (I or II) 41.4 32.9 to 50.2 48.6 36.4 to 60.8 33.3 22.0 to 46.3 27.3 10.7 to 50.2
Morphology
Total type I iEOC 19 10 9 5
Low-grade serous 5 1 4 0
Low-grade endometrioid 8 4 4 1
Clear cell 5 4 1 4
Mucinous 1 1 0 0
Total type II iEOC 109 58 51 11
High-grade serous 89 44 45 8
High-grade endometrioid 8 5 3 1
Unspecified adenocarcinoma 10 8 2 1
Carcinosarcoma (MMT) 2 1 1 1
Unclassified† 5 2 3 6
Abbreviations: CA-125, cancer antigen 125; iEOC, invasive epithelial ovarian and/or tubal cancer; IQR, interquartile range; MMT, malignant mesenchymal tumor;
ROC, risk of ovarian cancer.
Includes a case reported as mixed high-grade adenocarcinoma with serous and clear cell features and focal squamous differentiation.
†Morphology could not be determined because only cytology was undertaken.
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(Table 3). If the 12 screen-detected and three screen-negative primary
peritoneal cancers (PPCs)were included, sensitivity, specificity, andPPV
were85.3%(95%CI,79.1%to90.3%),99.8%(95%CI,99.8%to99.8%),
and 22.7% (95%CI, 19.5% to 26.1%), respectively. If we extended per-
formance characteristics to include iEOCs diagnosed up to 24 months
fromdate of last scan/CA-125 assay performed during incidence screen-
ing, sensitivity for iEOCswas 74.4%.
Of the 640 women who had screen-positive surgery, 31 had
nonovarian cancers, and 441 had normal or benign pathology (Table
1; Appendix Table A4, online only). An intraoperative or early post-
operative complication was reported in 20 of the 441 women (4.5%;
95%CI, 2.8% to 6.9%). Twelve of these women had amajor compli-
cation or significant sequelae (Appendix Table A5, online only).
DISCUSSION
In the largest ovarian cancer screening trial that we are aware of, a risk
algorithm using serial biomarker measurement doubled the number
of screen-detected cancers compared with a single-threshold rule. Of
the 155womenwith iEOCs, theROCAdetected 86.4%whereas using
annual serum CA-125 fixed cutoffs of more than 35, more than 30,
and more than 22 U/mL would have identified only 41.3%, 48.4%,
and 66.5%, respectively. Our data provide prospective evidence of the
improvement that CA-125 velocity analysis brings to iEOC detection
comparedwith a predetermined cutoff. The impact of such screening
on ovarian cancer mortality will be known later in 2015 when
follow-up is complete. However, our current findings are of immedi-
ate importance because they highlight the need to examine serial
change in biomarker levels in the context of screening and early detec-
tion of cancer. Reliance on predefined single-threshold rules may
result in biomarkers of value being discarded.
The encouraging sensitivity (85.8%) and specificity (99.8%) for
detecting iEOCs in low-riskpostmenopausalwomennotedduring the
prevalence screen persisted during incidence screening.9 The high
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Fig 3. Plot of all multimodal screening
annual cancer antigen 125 (CA-125) mea-
surements over time on a log scale, in-
cluding truncation. Superimposed are the
serial measurements for 155 invasive ep-
ithelial ovarian and/or tubal cancers with
the large circles representing the final
screen before diagnosis, either true posi-
tive (n  133; gold lines and markers) or
false negative (n  22; blue lines and
markers). The red line indicates one pa-
tient in whom the risk of ovarian cancer
algorithm recommended surgery, but it
was not performed following clinical eval-
uation. The black horizontal lines represent
CA-125 cutoffs of 35, 30, and 22 U/mL.
NOTE. 262 CA-125 values truncated above
100 U/mL and 174 CA-125 values truncated
below 2 U/mL.
CA125 ROC curve
ROCA score ROC curve
Multimodal screening arm = (sensitivity, 85.8; specificity, 99.8)
MROCA classified as normal v intermediate/elevated = (sensitivity, 87.1; specificity, 87.6)
MCA125  based on 35U/ml cut point = (sensitivity, 41.3; specificity, 97.5)
MCA125  based on 30U/ml cut point = (sensitivity, 48.4; specificity, 95.9)
MCA125  based on 22U/ml cut point = (sensitivity, 66.5; specificity, 89.2)
(sensitiv ty, 85.8; specific ty, 99.8)
CA 125 ROC curve AUC, 0.869; 95% CI, 0.839 to 0.898
ROCA score ROC curve AUC, 0.915; 95% CI, 0.883 to 0.946
P = .0027
ROCA classified as normal v intermediate/ l vated (sen itivity, 87.1; specificity, 87.6)
CA125  based on 35 U/mL cut point  (sensitivity, 41.3; specificity, 97.5)
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Fig 4. Risk of ovarian cancer (ROC) curves based on the performance
characteristics of annual cancer antigen 125 (CA125) measurement alone and
annual risk of ovarian cancer algorithm (ROCA) score alone. Overlaid points
represent the actual characteristics of the multimodal screening strategy, hypo-
thetical characteristics of annual ROCA classified as normal or abnormal (inter-
mediate/elevated) risk, hypothetical characteristics of annual CA125 using the
cutoff points of more than 35 U/mL (as in the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial), more than 30 U/mL (in clinical use), and more
than 22 U/mL (as suggested by other groups), respectively. P value of .0027 is
test of difference.
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sensitivity remained even when PPC was included as an outcome
measure. This was reassuring given that PPC probably shares com-
mon origins with primary high-grade serous iEOCs.15 The ROCA
increases sensitivity by personalizing the interpretation of serial bio-
marker values.This explains thehigher sensitivityobserved inour trial
compared with other trials in which a single-threshold CA-125 rule
was used—67% in thePLCO trial16 (four rounds of screening includ-
ing prevalence) and 77% in the Shizuoka Cohort Study.17
Overall, 41.4%(55of133)ofwomenweredetectedwith stage Ior
II disease. A majority (82.0%) of screen-detected iEOCs were aggres-
sive type II, which are associated with the highest mortality rates.18
This is reassuring, given the concern that screening detects more
indolent cancers. In the Shizuoka Cohort Study, 48% of screen-
detected cancers were type I mucinous and clear cell iEOCs.17
The strategy involved at least one repeat test such that the median
time fromannual screen to surgerywas20weeks.The intervalwas signif-
icantly longer in subgroupA (30weeks) comparedwith subgroup B (12
weeks) because women with annual CA-125 levels in the normal range
requiredmore repeat testing. Despite this, there was a higher proportion
of stage I or II iEOCs in subgroupA.The latter coupledwith the fact that
ovarian cancers double every twoandhalfmonths,19 suggests thatmodi-
fications to the screening strategy that could decrease this interval may
haveanadditional impactontumorstageandvolume.Thiscouldinclude
decreasing the 3-month interval to repeat CA-125 testing following an
intermediateROCandmeasuring levels of a secondbloodbiomarker
such as HE420,21 in intermediate-risk annual samples. Although
HE4 does not improve CA-125 lead time,22,23 it could help confirm
ovarian cancer risk and reduce time to surgery. In the presence of
an increasing CA-125, HE4 was increased in samples from 27 of 39
womenwith ovarian cancer in the PLCO trial.21 TVSdoes not seem
tohave the resolution to detect iEOCat lowCA-125 levels. Twenty-
nine (41%) of 70 women with iEOCs in subgroup A had no
abnormality on the initial level II scan, and TVS was abnormal in
only 17 of the 39women in the study byUrban et al.21 The potential
of newer technology such as contrast-enhanced TVS with targeted
microbubbles warrants assessment in this context.24
For each iEOC detected, four additional women underwent
surgery. These figures are slightly higher than previously reported
in trials using the ROCA9,25,26 but lower than the 19.516 and 3317
surgeries undertaken for each cancer detected in trials using other
screening strategies. Excess surgical morbidity in patients with
false-positive diagnoses is a key concern, especially with increasing
comorbidity in the older women. In our study, the rate of compli-
cations in women with benign or normal histology, most of whom
underwent laparoscopic bilateral salpingo-oophorectomy, was 4.5%.
Similar rates have been reported in women at high-risk of ovarian
cancer undergoing risk-reducing salpingo-oophorectomy (3.9%).27
Key strengths of our trial are the scale, the multicenter setting
within the United Kingdom health service, detailed screening and
management protocols implemented by a dedicated local and cen-
tral team, Web-based bespoke trial management system, high
compliance with screening, and independent blinded outcome
review. Completeness of data on screen-negative and/or interval
cancers in the year following the end of screening (2012) was
ensured by postal follow-up of all women in April 2014, coupled
with cancer registry updates in July 2014. The limitations relate
mainly to the long duration, a necessary feature of randomized
controlled trials with mortality as the primary end point, and the
associated improvements in clinical management over that period.
A healthy volunteer effect reduced the expected number of cancers
in the control arm and thereby further lengthened the trial.28
However, although these issues are pertinent to this analysis, they
will not affect the primary intention-to-treat mortality analysis.
Table 3. Performance Characteristics of MMS Incidence Screening for Malignant Ovarian (C56), Tubal (C57.0), and Primary Peritoneal (C48.2) Neoplasm
Characteristic
Ovarian and Fallopian
Tube Cancers
Ovarian, Fallopian Tube,
and Primary Peritoneal
Cancers
No. 95% CI No. 95% CI
No. of women-years 296,911 296,911
No. of surgeries 640 640
Primary ovarian (C56) and tubal (C57.0) malignancies and primary peritoneal cancer (C48.2) within 1
year of screen (includes borderline and ovarian neoplasm of uncertain behavior)
Screen positive 154 166
Screen negative 32 35
Sensitivity 82.8 76.6 to 87.9 82.6 76.6 to 87.6
Specificity 99.8 99.8 to 99.9 99.8 99.8 to 99.9
PPV 24.1 20.8 to 27.6 25.9 22.6 to 29.5
No. of operations per screen positive 4.2 3.9
Primary invasive epithelial ovarian, tubal, and primary peritoneal malignancies within 1 year of
screen (excludes borderline epithelial ovarian neoplasms)
Screen positive 133 145
Screen negative 22 25
Sensitivity 85.8 79.3 to 90.9 85.3 79.1 to 90.3
Specificity 99.8 99.8 to 99.8 99.8 99.8 to 99.8
PPV 20.8 17.7 to 24.1 22.7 19.5 to 26.1
No. of operations per screen positive 4.8 4.4
NOTE. All codes are International Statistical Classification of Diseases and Related Health Problems, 10th revision (ICD-10).
Abbreviations: MMS, multimodal strategy; PPV, positive predictive value.
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In conclusion, our data support use of velocity-based algorithms
as opposed to a predefined single-threshold rule in cancer screening
strategies that use blood biomarkers.
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GLOSSARY TERMS
biomarker: a functional biochemical or molecular indicator of
a biologic or disease process that has predictive, diagnostic,
and/or prognostic utility.
CA-125 (cancer antigen 125): a protein produced by the
fallopian tubes, the endometrium, and the lining of the abdomi-
nal cavity (peritoneum). CA-125 is a tumor marker present in
higher than normal amounts in the blood and urine of patients
with certain cancers. Typically, women with ovarian cancer have
high levels of CA-125. Other conditions associated with increased
levels of CA-125 include endometriosis, pancreatitis, pregnancy, normal
menstruation, and pelvic inflammatory disease. CA-125 levels may be
used to help diagnose ovarian cancer and to determine whether these
tumors are responding to therapy. The normal range for CA-125 is less
than 35 U/mL and less than 20 U/mL for women who have been treated
for ovarian cancer. Women with ovarian cancer may show values higher
than 65 U/mL.
positive predictive value: the probability of a positive test result
being truly positive.
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Appendix
Table A1. ICD-10 Codes for Notes Reviewed by the Outcomes Committee
ICD-10 Code Description
C56 Malignant neoplasm of ovary
C57.0 Malignant neoplasm of fallopian tube
C57.4 Uterine adnexa, unspecified
C57.7 Other specified female genital organs
C57.8 Malignant neoplasm of overlapping lesion of female genital organs
C57.9 Malignant neoplasm of female genital organ, unspecified
C48.0 Retroperitoneum
C48.1 Specified parts of peritoneum
C48.2 Malignant neoplasm of peritoneum, unspecified
C48.8 Overlapping lesions of retroperitoneum and peritoneum
C76.2 Malignant neoplasm of abdomen
C76.3 Malignant neoplasm of pelvis
C80 Malignant neoplasm without specification of site
D07.3 Carcinoma-in-situ of other or unspecified female genital organ
D28.2 Benign neoplasm of fallopian tube
D28.9 Benign neoplasm of female genital organ, unspecified
D36.9 Benign neoplasm of unspecified site
D39.1 Neoplasm of uncertain or unknown behavior of ovary
D39.9 Neoplasm of uncertain or unknown behavior of female genital organ, unspecified
Abbreviation: ICD-10, International Statistical Classification of Diseases and Related Health Problems (10th revision).
Table A2. Reasons Why Screens That Should Have Been Performed Were Not Undertaken
Reason Screen Was Not Performed No. of Screens No. of Women
Died 6,945 1,781
Decided to discontinue 73,632 16,393
Ovaries removed 4,505 1,060
Cancer diagnosed 3,425 953
Over-ran previous screen 3,105 2,874
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Table A3. Results of Incidence Screens
Incidence Screens
Woman-Years
No. %
Level 1 screen 296,911 100
Normal ROC, returned to annual screening 267,327 90.0
Intermediate ROC, referred for repeat level 1 screen 25,133 8.5
Elevated ROC, referred for level 2 screen 4,451 1.5
Repeat level 1 CA-125† 24,788 8.3
Returned to annual screening 21,234 85.7
Referred for level 2 screen 3,355 13.5
Did not complete all repeat screens 199 0.8
Level 2 screen† 7,323 2.5
Returned to annual screening 2,988 40.8
Referred for clinical assessment 1,023 14.0
Referred for repeat level 2 screen 3,312 45.2
Repeat level 2 screen† 2,766 0.9
Returned to annual screening 960 34.7
Referred for clinical assessment 1,806 65.3
Clinical assessments‡ 3,329 1.1
Screen-positive surgery 640 0.2
Diagnostic laparoscopy 17 2.7
Operative laparoscopy 356 55.6
Combined laparoscopy and laparotomy 42 6.6
Laparotomy 206 32.2
Imaging-guided cytology and/or biopsy 15 2.3
Other 4 0.8
Abbreviations: CA-125, cancer antigen 125; ROC, risk of ovarian cancer.
Denominators for header rows are number of incidence screens. Denominators for subsequent rows are numbers of women who underwent a specific screen.
†Difference in numbers between those who were recommended tests and number who underwent test is because of noncompliance.
‡In all, 109 (29  35  45) women withdrew before a clinical assessment was performed and 609 (55  5  29  136  384) additional women were clinically
evaluated before completing all protocol screens.
Table A4. Screen-Detected Nonovarian, Tubal, or Primary Peritoneal Cancer
Cancer Type No. of Women
Women with other nonovarian or tubal cancers not involving the ovaries (n  19)
Appendiceal 2
Endometrial 8
Lymphoma 3
Malignant neoplasm of unknown but not ovarian or tubal origin 1
Breast 1
Colorectal 1
Pancreatic 1
Liver 1
Renal 1
Women with other nonovarian or tubal cancers involving the ovaries (secondary ovarian neoplasm; n  12)
Appendiceal 1
Breast 3
Colorectal 3
GI 2
Lymphoma 1
Endometrial 2
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Table A5. Details of the Complications in Women Who Had Normal Ovaries or Benign Pathology at Screen-Positive Surgery
Intra- and Early Postoperative Complications
Women
No. %
Major
Intraoperative episode of severe tachycardia with asystole requiring cardiopulmonary resuscitation 1
Bowel obstruction 4
Bowel injury 2
Hemorrhage† 3
Wound dehiscence requiring resuturing 1
Significant ileus 1
Minor
Wound infection requiring antibiotics 5
Chest infection 1
Diarrhea and vomiting 1
Perforation of uterus, urinary retention, and UTI 1
Total number of benign surgeries with complications 20
Total number of benign surgeries 441
Complication rate 4.5
Abbreviation: UTI, urinary tract infection.
One small bowel obstruction from port site hernia, one subacute bowel obstruction requiring readmission.
†One from rectus sheet bleed, one from umbilical port site hematoma, one two-unit transfusion.
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